Across TCGA pan-cancer cohorts, TAF9B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TAF9B data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TAF9B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TAF9B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where TAF9B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.902	0.487	.002	18	view →
LUAD	OS	Tertile	II,III,IV	0.825	0.300	.014	12	view →
HNSC	DFS	Quartile	All	1.000	0.748	.016	7	view →
LSCC	OS	Median	II,III,IV	0.862	0.652	.011	6	view →
UCEC	DFS	Median	II,III,IV	0.826	1.000	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TAF9B tumor-vs-normal RNA expression · all TAF9B data types